Physician profile
Yi Zhang
NPI 1467652172
$5,581.10
in general payments reported to CMS, 2019-2025
29 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $485 · 2022: $1,449 · 2023: $835 · 2024: $1,106 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $1,084.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $772.94 | 2019-2025 | |
| Amgen INC. | $746.03 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.18 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $433.78 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.89 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $181.89 | 2019 | |
| Allergan, INC. | $161.57 | 2019 | |
| Boston Scientific Corporation | $141.97 | 2022-2025 | Watchman Flx, Watchman |
| W. L. Gore & Associates, INC. | $136.63 | 2024 | Gore Cardioform Septal Occluder |
| Pfizer INC. | $130.47 | 2020-2024 | |
| Lexicon Pharmaceuticals, INC. | $129.74 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $128.42 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $116.77 | 2019-2025 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $108.83 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $99.04 | 2019 | |
| Ucb, INC. | $76.77 | 2022 | |
| Abbott Laboratories | $57.91 | 2019-2023 | Cardiomems |
| Scpharmaceuticals INC. | $50.62 | 2024 | |
| Biotronik INC. | $48.45 | 2020 | |
| Chiesi USA, INC. | $46.36 | 2022-2023 | Kengreal, Cleviprex |
| Amarin Pharma, INC. | $39.01 | 2019 | |
| Cvrx, INC. | $29.64 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $24.22 | 2019-2022 | |
| Abiomed | $23.17 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.46 | 2025 | |
| Medtronic Vascular, INC. | $19.10 | 2020 | |
| Esperion Therapeutics, INC. | $18.26 | 2024 | Nexletol |
| Philips North America LLC | $16.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.